This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Assess whether Risk Parity or index funds better suit your retirement plan by examining diversification, cost, and potential risk/return trade-offs.
27,926 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Regulatory tightening is reshaping crypto’s path. Barabash argues the most regulated platforms may become the biggest...
Bitcoin eyes a pivotal test near the $58,000 zone as ETF-driven demand falters. If that support cracks, bitcoin still...
A notable new stake in Kyndryl signals growing confidence from a private equity–style shop. This deep dive explains w...
As America marks its 250th anniversary, a landmark IPO led by Elon Musk tests market appetite and rekindles questions...
AI chatbots offer big benefits for learning and managing crypto, but risks exist. This article explains how most chat...
A new collaboration between TSMC and Winbond intends to ease DRAM bottlenecks for AI workloads. It’s framed by analys...
The flagship Dubai crypto conference announced a postponement to 2027 amid ongoing regional conflict, signaling a bro...
With $1,000, you can build a resilient, diversified starter portfolio. This guide shows how to pick the best stocks w...
As Silicon Valley confronted its latest liquidity scare, a circle of less-visible players stepped in to steady payrol...
A Senate committee greenlit the CLARITY Act in a 15-9 vote, sending the bill to the full chamber. Markets jumped as X...
Howard Lindzon explains that seed investing hinges on a power-law mindset: most bets fail, but one or two extraordina...